Concerns and Innovations in Tablet Splitting and Scoring - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Concerns and Innovations in Tablet Splitting and Scoring
A roundtable discussion of the challenges and innovations in tablet splitting featuring Freeman Technology, Accu-Break Pharmaceuticals, and Medelpharm.

Pharmaceutical Technology
pp. s29-s34

PharmTech: When manufacturers are developing a tablet designed to be scored or subdivided, what tests are necessary to ensure stability? How does patient compliance factor into these decisions?

Freeman (Freeman Technology): Stability raises issues around the mechanical properties of the tablet, for example, can it be broken into two equally useful doses without crumbling, and is the finished product stable despite the score? Once again, powder characterization can play a useful role here in product and process optimization. For instance, one of the factors that influences tablet hardness and friability is the consistency of the die filling, which in turn is impacted by the characteristics of the powder blend. Even if the die can be filled uniformly at a commercially viable press speed, it is vital that the entrained air is rapidly released during compression and compaction, as retention can lead to capping and lamination. Retention is especially a problem for larger tablets that are more likely to be scored. The ability of the blend to release air can be quantified using parameters such as permeability and through dynamic characterisation of aerated powders. Finally, the response of the powder to compression can be directly measured via compressibility testing. In summary, comprehensive multifaceted powder characterization supports the development of optimized formulations and more exacting processes, both of which are required to produce well-engineered, mechanically stable scored tablets that are easy for patients to use.

PharmTech: FDA is currently working on draft guidance for tablet scoring. If implemented, how could such guidance affect analytical approaches for scored tablets, both in terms of new developments and demands from the industry?

Freeman (Freeman Technology): Increased focus by the FDA on scored tablets intensifies the requirement for manufacturers to adopt a rigorous quality-by-design (QbD) approach to their tablet development processes. Analytical approaches that can lead to a better understanding of critical-to-quality parameters, such as content uniformity and mechanical stability as outlined above are, therefore, likely to become increasingly important. Properties that predict blending performance and how the blend will subsequently perform in the tableting press are especially valuable. For example, returning to the issue of air entrainment and release, processing powders with low permeability at high rates can ultimately lead to trapped air building up in the powder at all stages of the press due to fast powder flow rates and recycle. The net result is an eventual degradation in tablet quality. This is just one of many illustrations of how powder property data can help processors make sound decisions about what equipment to use and what production rates to target for efficient scored tablet manufacture.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here